Saturday 17 October 2026
Export ALDX’s income statement to Excel — free account
Aldeyra Therapeutics, Inc.
ALDX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.8%, free cash flow grew 46.1% and total debt rose 1.33%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.70
0.04
−5.41%
Follow ALDX
Aldeyra Therapeutics, Inc. (ALDX) P/E ratio
Aldeyra Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. | n/m |
| CELU Celularity, Inc. compare | n/m |
| INMB INmune Bio, Inc. compare | n/m |
| CLNN Clene Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| IMA ImageneBio, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)